No Data
Humanwell Healthcare (600079.SH): HWH340 tablets have obtained the approval notice for clinical drug trials.
On January 21, Gelonghui reported that Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. (referred to as the "Research Institute Co., Ltd.") recently received the "Drug Clinical Trial Approval Notification" for HWH340 tablets issued by the National Medical Products Administration. The Research Institute Co., Ltd. first obtained the clinical trial notification for this product in December 2016, with the application name WXFL10040340 capsules and the intended indications as: this product is intended for malignant solid tumors with BRCA mutations or deletions and overexpression of PARP enzymes, such as ovarian cancer.
Humanwell Healthcare (600079.SH): Carbamazepine sustained-release tablets have received FDA approval number from the USA.
On January 20, Gelonghui reported that Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., has received the approval number from the USA Food and Drug Administration (FDA) for the carbamazepine extended-release tablets, which are indicated for the treatment of epilepsy and trigeminal neuralgia.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
GF SEC: VERTEX JPM meeting update, focusing on the progress in the fields of domestic enterprise pain and kidney disease.
The success of Suzetrigine offers hope for the development of the Nav1.8 target, and based on its inherent mechanism advantages, it is expected to bring a new, safer, and more effective therapy for pain patients.
Humanwell Healthcare (600079.SH): The controlling Shareholder has signed the restructuring investment agreement.
On January 15, Gu Longhui reported that Humanwell Healthcare (600079.SH) announced that the company received a notification from the manager of Contemporary Technology regarding the signing of the restructuring investment agreement for Wuhan Contemporary Technology Industry Group Co., Ltd.'s restructuring case. The manager of Contemporary Technology organized an investor review meeting on December 31, 2024, to conduct investor selection work, under the supervision of the Wuhan Intermediate Court and the Discipline Inspection and Supervision Committee of the Wuhan East Lake New Technology Development Zone, as well as notarized by the Wuhan Xiangxin Notary Public Office. Each investor presented and answered questions on-site. After a fair, just, and independent evaluation by the judges, China Merchants Chuangke ranked first in scoring.
Recent 6.9% Pullback Isn't Enough to Hurt Long-term Humanwell Healthcare (Group)Ltd (SHSE:600079) Shareholders, They're Still up 45% Over 5 Years
The Market Doesn't Like What It Sees From Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Yet
